The second-generation ALK TKIs alectinib (CH5424802/ RO5424802) and ceritinib (LDK378) also showed promising activity in controlling ALK(+) NSCLC in phase 3 trials (4, 5). This evidence concerns the gene ALK and non-small cell lung carcinoma.